Last edition
News about "Antibody-Drug Conjugate "
FDA Grants BTD to Raludotatug Deruxtecan for Platinum-Resistant Ovarian Cancer
This is the first BTD granted for Raludotatug Deruxtecan, the second for the Daiichi Sankyo-Merck partnership and the 15th across Daiichi Sankyo’s oncology portfolio, marking a significant milestone in the companies’ joint efforts to develop innovative cancer therapies.
Antibody-Drug Conjugate | 16/09/2025 | By Dineshwori
LOTTE BIOLOGICS Enters Contract Manufacturing Partnership with US Biopharma
South Korea’s LOTTE BIOLOGICS has signed a late-stage to commercial contract manufacturing agreement with a US-based global biopharmaceutical company.
Antibody-Drug Conjugate | 02/09/2025 | By Dineshwori | 121
Cohance Lifesciences to Invest USD 10 Million to Expand cGMP Bioconjugation Capabilities in US
Cohance Lifesciences will invest USD 10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary NJ Bio, strengthening its integrated Antibody-Drug Conjugate manufacturing capacity for global innovators.
Antibody-Drug Conjugate | 13/08/2025 | By Mrinmoy Dey
SPARC Incorporates Wholly Owned Subsidiary Genokine Biotech in Vadodara
Sun Pharma Advanced Research Company Ltd. (SPARC) has incorporated a new wholly owned subsidiary, Genokine Biotech Ltd., with its registered office in Vadodara, Gujarat.
Antibody-drug Conjugate | 09/07/2025 | By Dineshwori | 188
SPARC Submits IND Application for SBO-154 to USFDA
Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.
Antibody-drug Conjugate | 31/03/2025 | By Aishwarya | 190
Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate
IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.
Antibody Drug Conjugate | 02/01/2025 | By Aishwarya | 196
Samsung Biologics Announces Manufacturing Deal with European Pharmaceutical Company
Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.
Antibody-drug Conjugate | 20/11/2024 | By Aishwarya | 195
Chime Biologics and Waterstone to Advance ADC Development and Manufacturing
Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.
Antibody-Drug Conjugate | 13/11/2024 | By Aishwarya | 155
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy